SAN DIEGO, March 15, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced preliminary data from the Toca 6 Phase 1 study in advanced solid tumors will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018, held April 14-18 in Chicago. New data from Tocagen's Phase 1 resection trial demonstrating the immune profile of the tumor microenvironment helps predict response in patients with high-grade glioma receiving Toca 511 & Toca FC will also be presented.
Full posters will be placed on Tocagen's website following the presentations.
Presentation Type: Poster (Abstract: CT067)
Title: A phase 1b study of Toca 511, a retroviral replicating vector, followed by Toca FC in patients with advanced cancer
Presenter: Jaime Merchan, M.D., director, Phase 1 clinical trials program at Sylvester Comprehensive Cancer Center, part of UHealth, the University of Miami Health System; associate professor of medicine at the University of Miami Miller School of Medicine
Date and Time: Monday, April 16, 8:00 a.m. - 12:00 p.m. CT
Presentation Type: Poster (Abstract: 5630)
Title: Immune profile of tumor microenvironment helps predict response in patients treated with an investigational immunotherapeutic consisting of a retroviral replicating vector (Toca 511) and an extended-release formulation of 5-fluorocytosine (Toca FC)
Presenter: Derek Ostertag, Ph.D., senior director of R&D Diagnostics at Tocagen
Date and Time: Wednesday, April 18, 8:00 a.m. - 12:00 p.m. CT
About Toca 511 & Toca FC
Tocagen's lead product candidate is a two-part cancer-selective immunotherapy comprised of an investigational biologic, Toca 511, and an investigational small molecule, Toca FC. Toca 511 is a retroviral replicating vector (RRV) that selectively infects cancer cells and delivers a gene for the enzyme, cytosine deaminase (CD). Through this targeted delivery, only infected cancer cells carry the CD gene and produce CD. Toca FC is an orally administered prodrug, 5-fluorocytosine (5-FC), which is converted into an anti-cancer drug, 5-fluorouracil (5-FU), when it encounters CD. 5-FU kills cancer cells and immune-suppressive myeloid cells resulting in anti-cancer immune activation and subsequent tumor killing.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3 trial for recurrent high-grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of HGG. For more information about Tocagen, visit www.tocagen.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our business plans and objectives, timing and success of our clinical trials and planned clinical trials, timing of results from our clinical trials and our plans regarding selection of additional product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost and timing of our product candidate development activities and planned clinical trials; our ability to execute on our strategy; regulatory developments in the United States and foreign countries; and our estimates regarding expenses, future revenue and capital requirements. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Tocagen's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Tocagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
The Trout Group
View original content with multimedia:http://www.prnewswire.com/news-releases/tocagen-to-present-preliminary-toca-6-phase-1-data-and-immune-profiling-data-at-the-american-association-for-cancer-research-aacr-annual-meeting-2018-300614350.html
SOURCE Tocagen Inc.